

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated 28 October 2014 (the “**Prospectus**”) of Austar Lifesciences Limited (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

Unless defined herein, terms used in this announcement shall have the same meanings as those defined in the Prospectus.

*This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933 (as amended) (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There is not and it is not currently intended for there to be any public offering of securities of the Company in the United States.*

*In connection with the Global Offering, Haitong International Securities Company Limited, as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offer. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).*

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on the 30th day after the date of closing of the application lists under the Hong Kong Public Offer. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.



AUSTAR

Austar Lifesciences Limited

奧星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	:	125,000,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	:	12,500,000 Shares (subject to adjustment)
Number of International Placing Shares:	:	112,500,000 Shares (subject to adjustment and the Over-allotment Option)
Maximum Offer Price	:	HK\$3.12 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	:	HK\$0.01 per Share
Stock code	:	6118

Sole Sponsor



Haitong International Capital Limited

Sole Global Coordinator



Haitong International Securities Company Limited

Joint Bookrunners and Joint Lead Managers



Haitong International Securities
Company Limited



BOCOM International Securities
Limited

Application has been made by the Company to the Listing Committee of the Stock Exchange for the grant of the approval for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering and the Capitalisation Issue, as further described in the Prospectus, including any Shares which may be issued by the Company in connection with the Over-allotment Option. Assuming that the Hong Kong Public Offer becomes unconditional at or before 8:00 a.m. in Hong Kong on Friday, 7 November 2014, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Friday, 7 November 2014. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.austar.com.hk.

The Global Offering comprises the Hong Kong Public Offer of initially 12,500,000 Shares (subject to adjustment) and the International Placing of initially 112,500,000 Shares (subject to the Over-allotment Option and adjustment) representing 10% and 90% of the total number of Offer Shares initially being offered under the Global Offering, respectively. In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, which is exercisable by the Sole Global Coordinator (for itself and on behalf of the other International Underwriters), to require the Company to allot and issue up to 18,750,000 additional new Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering, in connection with over-allocation in the International Placing, if any, subject to the same terms and conditions as the other Offer Shares.

The allocation of the Shares between the Hong Kong Public Offer and the International Placing is subject to adjustment as stated in the paragraph headed "*Hong Kong Public Offer*" under the section headed "*Structure and conditions of the Global Offering*" in the Prospectus. Allocation of the Offer Shares pursuant to the International Placing will be effected in accordance with the book-building process and based on a number of factors, including the level and timing of demand, the total size of the relevant investor's invested assets or equity assets in the relevant sector and whether or not it is expected that the relevant investor is likely to buy further Offer Shares, and/or hold or sell its Offer Shares, after the listing of the Offer Shares on the Stock Exchange. Such allocation is intended to result in a distribution of the Shares on a basis which would lead to the establishment of a solid professional and institutional shareholder base to the benefit of our Company and our Shareholders as a whole. In the event the Over-allotment Option is exercised, an announcement will be made by the Company and the announcement will be available at the websites of the Company at www.austar.com.hk and the Stock Exchange at www.hkexnews.hk.

Subject to the grant of listing of, and permission to deal in, the Shares on the Stock Exchange as well as the compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$3.12 per Offer Share and is expected to be not less than HK\$2.29 per Offer Share. Applicants under the Hong Kong Public Offer are required to pay, on application, the maximum Offer Price of HK\$3.12 per Offer Share plus brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% payable on each Offer Share, equal to a total of HK\$3,151.44 for one board lot of 1,000 Shares.

If the Offer Price, as finally determined in the manner described in the paragraph headed "*Price determination of the Global Offering*" in the section headed "*Structure and conditions of the Global Offering*" in the Prospectus, is less than the maximum price of HK\$3.12 per Share, appropriate refund payments (including the brokerage, SFC transaction levy and Stock Exchange trading fee attributable to the surplus application monies) will be made to successful applicants, without interest. Further details are set out in the paragraph headed "*13. Refund of application monies*" in the section headed "*How to apply for the Hong Kong Offer Shares*" in the Prospectus.

Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and the related Application Forms.

IMPORTANT

Applicants who would like to be allotted Hong Kong Offer Shares in their own names should (i) complete and sign the **WHITE** Application Forms or (ii) submit applications online through the designated website of the **HK eIPO White Form** Service Provider at **www.hkeipo.hk** through the **HK eIPO White Form** service. Applicants who would like to have the allotted Hong Kong Offer Shares issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants maintained in CCASS should either (i) complete and sign the **YELLOW** Application Forms or (ii) give electronic application instructions to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Form, may be obtained during normal business hours from 9:00 a.m. on Tuesday, 28 October 2014 until 12:00 noon on Friday, 31 October 2014 from:

1. the following offices of the Hong Kong Underwriters:

Haitong International Securities Company Limited	22/F, Li Po Chun Chambers, 189 Des Voeux Road Central, Hong Kong
BOCOM International Securities Limited	9/F, Man Yee Building, 68 Des Voeux Road Central, Hong Kong
KGI Capital Asia Limited	41/F Central Plaza, 18 Harbour Road, Wanchai, Hong Kong
RHB OSK Securities Hong Kong Limited	12/F World-wide House, 19 Des Voeux Road Central, Hong Kong
SBI China Capital Financial Services Limited	Unit A2, 32/F, United Centre, 95 Queensway, Hong Kong
Bright Smart Securities International (H.K.) Limited	10/F Wing On House, 71 Des Voeux Road Central, Hong Kong

2. any of the following branches of the receiving bank:

The Bank of East Asia, Limited

District	Branch	Address
Hong Kong Island	Main Branch	10 Des Voeux Road Central, Central
	Shauiwan Branch	G/F, Ka Fook Building, 289-293 Shau Kei Wan Road, Shau Kei Wan
Kowloon	Prince Edward Branch	G/F, Hanley House, 776-778 Nathan Road, Prince Edward
	Kwun Tong Branch	7 Hong Ning Road, Kwun Tong
	East Tsim Sha Tsui Branch	Shop G3-G5, G/F, East Ocean Centre, 98 Granville Road, Tsim Sha Tsui
	Wong Tai Sin Branch	Shop UG15, Upper Ground Floor, Wong Tai Sin Plaza, Wong Tai Sin
New Territories	Shatin Plaza Branch	Shop 3-4, Level 1, Shatin Plaza, Shatin
	Tai Po Branch	62-66 Po Heung Street, Tai Po Market, Tai Po
	Tsuen Wan Branch	239-243 Sha Tsui Road, Tsuen Wan
	Metro City Plaza Branch	Shop 243, Level 2, Metro City Plaza I, 1 Wan Hang Road, Tseung Kwan O

Copies of the Prospectus, together with the **YELLOW** Application Form, may be obtained during normal business hours from 9:00 a.m. on Tuesday, 28 October 2014 until 12:00 noon on Friday, 31 October 2014 at the Depository Counter of HKSCC at 2nd Floor, Infinitus Plaza, 199 Des Voeux Road Central, Hong Kong or from your stockbroker.

The **WHITE** or **YELLOW** Application Form completed in accordance with the instructions printed thereon, together with a cheque or banker's cashier order payable to "The Bank of East Asia (Nominees) Limited – Austar Lifesciences Public Offer" should be deposited in the special collection boxes provided at any of the branches of receiving bank referred to above on such dates and during such time as specified in the Application Forms.

Applicants applying through the **HK eIPO White Form** service may submit applications through the designated website at **www.hkeipo.hk** from 9:00 a.m. on Tuesday, 28 October 2014 until 11:30 a.m. on Friday, 31 October 2014 or such later time as described in the section headed "*How to apply for the Hong Kong Offer Shares – 10. Effect of bad weather on the opening of the application lists*". CCASS Participants can input electronic application instructions from 9:00 a.m. on Tuesday, 28 October 2014 until 12:00 noon on Friday, 31 October 2014 or such later time as described in the section headed "*How to apply for the Hong Kong Offer Shares – 10. Effect of bad weather on the opening of the application lists*" in the Prospectus.

Please refer to the “*Structure and conditions of the Global Offering*” and “*How to apply for the Hong Kong Offer Shares*” sections in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offer.

The Company expects to announce the final Offer Price, the level of indication of interest in the International Placing, the level of applications in the Hong Kong Public Offer and the basis of allocation of Hong Kong Offer Shares on Thursday, 6 November 2014 in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese), and on the websites of the Company at **www.austar.com.hk** and the Stock Exchange at **www.hkexnews.hk**.

The results of allocations (with the successful applicants’ identification document numbers, where applicable) under the Hong Kong Public Offer will be made available through a variety of channels at the times and date and in the manner specified in the section entitled “*How to apply for the Hong Kong Offer Shares – 11. Publication of results*” in the Prospectus. The Company will not issue temporary documents of title or receipt for application fees received. Share certificates will only become valid certificates of title provided that the Hong Kong Public Offer has become unconditional in all respects and the right of termination described in the section entitled “*Underwriting – Underwriting arrangements and expenses – Hong Kong Public Offer – Hong Kong Underwriting Agreement – Grounds for termination*” has lapsed, which is expected to be at 8:00 a.m. on Friday, 7 November 2014.

Dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Friday, 7 November 2014. The Shares will be traded in board lots of 1,000 Shares each under the Company’s stock code 6118.

By Order of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 28 October 2014

As of the date of this announcement, Mr. Ho Kwok Keung, Mars, Mr. Chen Yuewu, Mr. Ho Kin Hung and Madam Zhou Ning are the executive Directors, Mr. Enzo Barazetti and Madam Ji Lingling are the non-executive Directors, and Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Raco Ivan Jordanov (alias Racho Jordanov) are the independent non-executive Directors.

Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese).